Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.52 CAD | -0.65% | +3.40% | -15.08% |
Apr. 11 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
Apr. 11 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.08% | 83.96M | |
+0.61% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.03% | 24.63B | |
-24.25% | 18.2B | |
+26.59% | 12.01B | |
-2.79% | 11.76B | |
+8.12% | 10.4B | |
-2.99% | 9.94B |
- Stock Market
- Equities
- ONC Stock
- News Oncolytics Biotech Inc.
- Oncolytics Biotech Brief: Announcing Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep "Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate"